PureTech Health Net Income Over Time
| PRTC Stock | USD 17.46 0.15 0.85% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out PureTech Health Performance and PureTech Health Correlation. Will Biotechnology sector continue expanding? Could PureTech diversify its offerings? Factors like these will boost the valuation of PureTech Health. Anticipated expansion of PureTech directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every PureTech Health data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.615 | Earnings Share 1.7 | Revenue Per Share | Quarterly Revenue Growth 5.427 | Return On Assets |
The market value of PureTech Health PLC is measured differently than its book value, which is the value of PureTech that is recorded on the company's balance sheet. Investors also form their own opinion of PureTech Health's value that differs from its market value or its book value, called intrinsic value, which is PureTech Health's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because PureTech Health's market value can be influenced by many factors that don't directly affect PureTech Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between PureTech Health's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PureTech Health should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, PureTech Health's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare PureTech Health PLC and related stocks such as Autolus Therapeutics, Neurogene, and Solid Biosciences LLC Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUTL | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (7.5 M) | (12.6 M) | (19.7 M) | (31.1 M) | (123.8 M) | (142.1 M) | (142.1 M) | (148.8 M) | (208.4 M) | (220.7 M) | (198.6 M) | (188.7 M) |
| NGNE | (10.5 M) | (10.5 M) | (7.7 M) | (8.7 M) | (23.8 M) | (21.9 M) | (37 M) | (50.2 M) | (31.6 M) | (69.4 M) | (33.3 M) | (50.5 M) | (55.2 M) | (36.3 M) | (75.1 M) | (67.6 M) | (64.2 M) |
| SLDB | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (21.5 M) | (52.1 M) | (74.8 M) | (117.2 M) | (88.3 M) | (72.2 M) | (86 M) | (96 M) | (124.7 M) | (112.2 M) | (117.8 M) |
| QSI | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (36.6 M) | (95 M) | (132.4 M) | (96 M) | (101 M) | (90.9 M) | (95.5 M) |
| LCTX | (700 K) | (16.5 M) | (21.4 M) | (43.9 M) | (36.4 M) | (47 M) | 33.6 M | (20 M) | (46 M) | (11.7 M) | (20.6 M) | (43 M) | (26.3 M) | (21.5 M) | (18.6 M) | (16.7 M) | (17.6 M) |
| BNTC | (6.4 M) | (6.4 M) | (6.4 M) | (10.8 M) | (8.8 M) | (18.5 M) | (4.4 M) | (8.6 M) | 2.9 M | (8.3 M) | (13.9 M) | (18.2 M) | (19.6 M) | (21.8 M) | (37.9 M) | (34.1 M) | (32.4 M) |
| ADCT | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (123.1 M) | (116.5 M) | (246.3 M) | (230 M) | (157.1 M) | (240.1 M) | (157.8 M) | (142.1 M) | (149.2 M) |
| ALMS | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (155 M) | (294.2 M) | (264.8 M) | (278.1 M) |
| RCKT | (6.1 M) | (6.1 M) | (6.1 M) | (7.6 M) | (9.5 M) | (68 M) | (42.9 M) | (29.5 M) | (74.5 M) | (83.2 M) | (146.7 M) | (169.1 M) | (221.9 M) | (245.6 M) | (258.7 M) | (232.9 M) | (221.2 M) |
| NMRA | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (237.3 M) | (130.9 M) | (235.9 M) | (243.8 M) | (219.4 M) | (230.4 M) |
PureTech Health PLC and related stocks such as Autolus Therapeutics, Neurogene, and Solid Biosciences LLC Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in PureTech Health PLC financial statement analysis. It represents the amount of money remaining after all of PureTech Health PLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| PureTech Health PLC | PRTC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 6 Tide Street, |
| Exchange | NASDAQ Exchange |
USD 17.46
Check out PureTech Health Performance and PureTech Health Correlation. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
PureTech Health technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.